# A Study of SC Administration of Trastuzumab (Herceptin) by SID at Home in HER2-Positive EBC Participants

> **NCT02040935** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 128 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Trastuzumab

## Key facts

- **NCT ID:** NCT02040935
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02-21
- **Primary completion:** 2018-09-14
- **Final completion:** 2018-09-14
- **Target enrollment:** 128 (ACTUAL)
- **Last updated:** 2019-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02040935

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02040935, "A Study of SC Administration of Trastuzumab (Herceptin) by SID at Home in HER2-Positive EBC Participants". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02040935. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*